On July 1st, 2024, NPR featured multiple AFAR grantee Matt Kaeberlein, PhD, in a segment on Rapamycin’s potential to address aging-related conditions.
Drawing on insights gained from Dog Aging Project, which he co-founded, Dr. Kaeberlein discussed the possible uses of Rapamycin that could extend healthspan and delay age-related diseases in humans.
Dr. Kaeberlein is a 2006 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient. He is also the 2011 recipient of AFAR’s Vincent Cristofalo Rising Star Award in Aging Research.
Explore “Rapamycin may slow aging. Here's one way the drug will be tested.” here.
